Literature DB >> 9876889

Quality of life in migraine and chronic daily headache patients.

M J Monzón1, M J Láinez.   

Abstract

Primary chronic headache can affect a patient's health-related quality of life (HQL). The Medical Outcomes Study Short Form (SF-36) questionnaire has been used to address this issue. We compare the impact of headache on the HQL of patients with migraine and chronic daily headache (CDH) using the SF-36 instrument. We analyzed a group of 115 consecutive patients; 62 migraine patients and 53 CDH patients completed the questionnaire. Patterns of disability were similar between the two groups, but CDH was marked by a lower level of health scales. Patients with CDH had a significantly worse pain score in physical functioning, role functioning (physical), bodily pain, general health perceptions, and mental health than patients with migraine headache. Our results in the migraine group were similar to findings in other publications, with the lowest scores in role functioning (physical) and bodily pain. There is no previous experience in CDH patients, but the present data suggest that the SF-36 questionnaire is valuable in determining the differences in functional status among headache types. These data suggest that the SF-36 is a reliable and valid measure of the HQL of patients with CDH, and may indeed prove to be valuable in studying the efficacy of therapeutic agents for this type of headache.

Entities:  

Mesh:

Year:  1998        PMID: 9876889     DOI: 10.1111/j.1468-2982.1998.1809638.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  23 in total

Review 1.  Psychiatric comorbidity of chronic daily headache: impact, treatment, outcome, and future studies.

Authors:  Shuu-Jiun Wang; Kai-Dih Juang
Journal:  Curr Pain Headache Rep       Date:  2002-12

2.  Correlation Between Life Events and Quality of Life in Patients with Medication-Overuse Headache.

Authors:  Ebru Altintaş; Başak Karakurum Göksel; Nilgün Taşkintuna; Çağla Saritürk
Journal:  Noro Psikiyatr Ars       Date:  2015-07-07       Impact factor: 1.339

Review 3.  Assessment of Quality of Life in Migraine.

Authors:  Özlem Taşkapilioğlu; Necdet Karli
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

Review 4.  Chronic migraine--classification, characteristics and treatment.

Authors:  Hans-Christoph Diener; David W Dodick; Peter J Goadsby; Richard B Lipton; Jes Olesen; Stephen D Silberstein
Journal:  Nat Rev Neurol       Date:  2012-02-14       Impact factor: 42.937

5.  Pain and health related functioning among employees.

Authors:  Peppiina Saastamoinen; Päivi Leino-Arjas; Mikko Laaksonen; Pekka Martikainen; Eero Lahelma
Journal:  J Epidemiol Community Health       Date:  2006-09       Impact factor: 3.710

6.  Quality of life assessment in migraine and relapsing remitting multiple sclerosis: self-perceived health is similar.

Authors:  Klaudia Duka Glavor; Marina Titlić; Gorka Vuletić; Anamarija Mrđen; Marina Maras Šimunić
Journal:  Neurol Sci       Date:  2019-07-17       Impact factor: 3.307

7.  The responsiveness of headache impact scales scored using 'classical' and 'modern' psychometric methods: a re-analysis of three clinical trials.

Authors:  M Kosinski; J B Bjorner; J E Ware; A Batenhorst; R K Cady
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

8.  A six-item short-form survey for measuring headache impact: the HIT-6.

Authors:  M Kosinski; M S Bayliss; J B Bjorner; J E Ware; W H Garber; A Batenhorst; R Cady; C G H Dahlöf; A Dowson; S Tepper
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

9.  Usefulness of the SF-8 Health Survey for comparing the impact of migraine and other conditions.

Authors:  Diane M Turner-Bowker; Martha S Bayliss; John E Ware; Mark Kosinski
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

10.  Reduction in the impact of chronic migraine with medication overuse after day-hospital withdrawal therapy.

Authors:  Susanna Usai; Licia Grazzi; Domenico D'Amico; Frank Andrasik; Gennaro Bussone
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.